NASDAQ:OPTN OptiNose (OPTN) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free OPTN Stock Alerts $1.01 +0.13 (+14.77%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.88▼$1.0150-Day Range$0.82▼$1.9452-Week Range$0.80▼$2.10Volume1.12 million shsAverage Volume1.92 million shsMarket Capitalization$114.17 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get OptiNose alerts: Email Address OptiNose MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside296.0% Upside$4.00 Price TargetShort InterestBearish2.84% of Shares Sold ShortDividend StrengthN/ASustainability-2.10Upright™ Environmental ScoreNews Sentiment0.57Based on 9 Articles This WeekInsider TradingSelling Shares$68,812 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.26) to ($0.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.12 out of 5 starsMedical Sector937th out of 5,424 stocksPharmaceutical Preparations Industry331st out of 2,550 stocks 3.5 Analyst's Opinion Consensus RatingOptiNose has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOptiNose has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.84% of the outstanding shares of OptiNose have been sold short.Short Interest Ratio / Days to CoverOptiNose has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in OptiNose has recently increased by 3.22%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOptiNose does not currently pay a dividend.Dividend GrowthOptiNose does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOptiNose has received a 60.30% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sumatriptan", "Nasal medication (R01)", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for OptiNose is -2.10. Previous Next 2.5 News and Social Media Coverage News SentimentOptiNose has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for OptiNose this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for OPTN on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OptiNose insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $68,812.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of OptiNose is held by insiders.Percentage Held by Institutions85.60% of the stock of OptiNose is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OptiNose are expected to grow in the coming year, from ($0.26) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptiNose is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptiNose is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsFW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.Click here. About OptiNose Stock (NASDAQ:OPTN)OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.Read More OPTN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPTN Stock News HeadlinesMay 2, 2024 | americanbankingnews.comHC Wainwright Comments on OptiNose, Inc.'s Q1 2024 Earnings (NASDAQ:OPTN)May 1, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for OptiNose (NASDAQ:OPTN)May 5, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 29, 2024 | bizjournals.comAfter key Xhance approval, Optinose outlines plan to quadruple sales and reach profitabilityApril 27, 2024 | finance.yahoo.comOptiNose, Inc. (OPTN)April 25, 2024 | investorplace.comWhy Is OptiNose (OPTN) Stock Up 12% Today?April 25, 2024 | globenewswire.comOptinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 millionApril 7, 2024 | msn.comOptinose to Present at Needham Virtual Healthcare ConferenceMay 5, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 6, 2024 | finance.yahoo.comOptiNose (NASDAQ:OPTN) shareholders have endured a 87% loss from investing in the stock five years agoApril 4, 2024 | globenewswire.comOptinose to Present at the Needham Virtual Healthcare ConferenceMarch 16, 2024 | finanznachrichten.deOptinose, Inc.: XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal PolypsMarch 16, 2024 | msn.comOptiNose granted FDA nod to expand labeling for sinusitis therapyMarch 15, 2024 | bizjournals.comBucks County's Optinose wins FDA approval for wider use of flagship productMarch 15, 2024 | globenewswire.comXHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal PolypsMarch 13, 2024 | bizjournals.comOptinose primed for FDA ruling on Xhance that could 'reshape' its futureMarch 10, 2024 | finance.yahoo.comUS$3.00: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest ResultsMarch 10, 2024 | seekingalpha.comOptiNose, Inc. (OPTN) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finance.yahoo.comOptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finance.yahoo.comOptiNose Full Year 2023 Earnings: EPS Beats ExpectationsMarch 7, 2024 | finance.yahoo.comOptiNose Inc (OPTN) Reports Decline in 2023 Revenue Amidst Preparations for Potential XHANCE ...March 7, 2024 | investorplace.comOPTN Stock Earnings: OptiNose Meets EPS, Beats Revenue for Q4 2023March 7, 2024 | finanznachrichten.deOptinose, Inc.: Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsMarch 7, 2024 | finance.yahoo.comOptinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsMarch 7, 2024 | msn.comOptiNose reports mixed results; initiates Q1 and FY24 outlookMarch 7, 2024 | washingtonpost.comOptiNose: Q4 Earnings SnapshotMarch 7, 2024 | globenewswire.comOptinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsSee More Headlines Receive OPTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptiNose and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/05/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OPTN CUSIPN/A CIK1494650 Webwww.optinose.com Phone(267) 364-3500FaxN/AEmployees132Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+296.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,480,000.00 Net Margins-50.06% Pretax Margin-49.99% Return on EquityN/A Return on Assets-33.05% Debt Debt-to-Equity RatioN/A Current Ratio0.60 Quick Ratio0.55 Sales & Book Value Annual Sales$70.99 million Price / Sales1.61 Cash FlowN/A Price / Cash FlowN/A Book Value($0.77) per share Price / Book-1.31Miscellaneous Outstanding Shares113,040,000Free Float110,552,000Market Cap$114.17 million OptionableNot Optionable Beta-0.10 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Ramy A. Mahmoud M.D. (Age 59)M.P.H., CEO & Director Comp: $731.59kMr. Michael F. Marino Esq. (Age 48)Chief Legal Officer & Corporate Secretary Comp: $604.24kMr. Anthony J. Krick (Age 43)Vice President & Chief Accounting Officer Mr. Jonathan NeelyVice President of Investor Relations & Business OperationsMs. Karen E. Brophy (Age 61)Chief Human Resources Officer & VP of Human Resources Mr. Paul Spence (Age 56)Chief Commercial Officer More ExecutivesKey CompetitorsCue BiopharmaNASDAQ:CUEPMV PharmaceuticalsNASDAQ:PMVPAllakosNASDAQ:ALLKBioXcel TherapeuticsNASDAQ:BTAIOramed PharmaceuticalsNASDAQ:ORMPView All CompetitorsInsiders & InstitutionsEasterly Investment Partners LLCBought 516,730 shares on 5/3/2024Ownership: 1.803%HighMark Wealth Management LLCBought 25,000 shares on 4/29/2024Ownership: 0.022%Rosalind Advisors Inc.Sold 344,091 shares on 4/25/2024Ownership: 4.032%Assenagon Asset Management S.A.Bought 50,662 shares on 4/24/2024Ownership: 0.077%Rice Hall James & Associates LLCSold 11,619 shares on 4/23/2024Ownership: 0.882%View All Insider TransactionsView All Institutional Transactions OPTN Stock Analysis - Frequently Asked Questions Should I buy or sell OptiNose stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPTN shares. View OPTN analyst ratings or view top-rated stocks. What is OptiNose's stock price target for 2024? 3 brokers have issued 1-year price targets for OptiNose's shares. Their OPTN share price targets range from $3.00 to $5.00. On average, they anticipate the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 296.0% from the stock's current price. View analysts price targets for OPTN or view top-rated stocks among Wall Street analysts. How have OPTN shares performed in 2024? OptiNose's stock was trading at $1.29 at the beginning of the year. Since then, OPTN stock has decreased by 21.7% and is now trading at $1.01. View the best growth stocks for 2024 here. When is OptiNose's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our OPTN earnings forecast. How were OptiNose's earnings last quarter? OptiNose, Inc. (NASDAQ:OPTN) announced its quarterly earnings data on Thursday, March, 7th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. The business had revenue of $19.87 million for the quarter, compared to analysts' expectations of $19.90 million. During the same period in the previous year, the company earned ($0.17) EPS. What guidance has OptiNose issued on next quarter's earnings? OptiNose updated its first quarter 2024 earnings guidance on Thursday, March, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $13.0 million-$13.0 million, compared to the consensus revenue estimate of $18.2 million. What other stocks do shareholders of OptiNose own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI), Idera Pharmaceuticals (IDRA), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Selecta Biosciences (SELB), VBI Vaccines (VBIV), Strongbridge Biopharma (SBBP) and SCYNEXIS (SCYX). When did OptiNose IPO? OptiNose (OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO. Who are OptiNose's major shareholders? OptiNose's stock is owned by many different institutional and retail investors. Top institutional investors include Rosalind Advisors Inc. (4.03%), Easterly Investment Partners LLC (1.80%), Rice Hall James & Associates LLC (0.88%), Assenagon Asset Management S.A. (0.08%) and HighMark Wealth Management LLC (0.02%). Insiders that own company stock include Anthony J Krick, Joseph C Scodari, Keith A Goldan, Michael F Marino III, Michael F Marino III, Michele Janis, Peter K Miller, Ramy A Mahmoud, Ramy A Mahmoud and Victor M Clavelli. View institutional ownership trends. How do I buy shares of OptiNose? Shares of OPTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OPTN) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe only AI company you should be looking atBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptiNose, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
